New drug review
Lytenava
Review section
| Field | Value |
|---|---|
| Drug | Lytenava (bevacizumab-vikg) |
| Indication reviewed | Neovascular age-related macular degeneration |
| Therapeutic category | Ophthalmic vascular endothelial growth factor (VEGF) inhibitors (intravitreal anti-VEGF monoclonal antibody) |
| Manufacturer | Outlook Therapeutics |
| Regulatory status | Approved July 24, 2026 |
| Data as of | September 28, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Indications
Table 1. FDA-approved indications
| Indications | Lytenava (bevacizumab-vikg) |
|---|---|
| “treatment of patients with neovascular (wet) age-related macular degeneration (nAMD)” | ✓ |
Trial in which efficacy was established
Pharmacokinetics
Table 2. Pharmacokinetic parameters
| Generic Name(s) | Bioavailability | Protein Binding | Metabolism | Excretion | Half-Life |
|---|---|---|---|---|---|
| Bevacizumab-vikg | Not reported | Not reported | Not reported | Not reported | Not reported |
Systemic exposure after intravitreal injection
Drug interactions
Table 3. Major drug interactions
No evidence found.
Contents of the prescribing information, which list no drug interactions section
Adverse drug events
Safety population and comparator in Table 4
Warnings and precautions
Contraindications
Dosing and administration
Table 5. Usual dosing regimens
See the current prescribing information for full details.
Devices, preparation, and single-eye use
Injection procedure and post-injection monitoring
Effectiveness
Table 6. Comparative clinical trials
Abbreviations: BCVA=best corrected visual acuity; CI=confidence interval; ETDRS=Early Treatment Diabetic Retinopathy Study; LS=least squares; nAMD=neovascular age-related macular degeneration; NI=non-inferiority
NORSE TWO eligibility, comparator regimen, p-value, and mean change in visual acuity, from the trial publication, which the prescribing information does not state
“Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients randomized to ONS-5010 received monthly intravitreal doses of 1.25 mg of ONS-5010, bevacizumab-vikg (Outlook Therapeutics) for 12 months. Patients randomized to ranibizumab received 0.50 mg of ranibizumab on days 0, 30, 60, 150, and 240 based on the PIER study dosing regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respectively, 41.7% and 23.1% of patients gained ≥ 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086]; P = 0.0052. The change in BCVA from baseline to 11 months was found to be 11.2 ± 12.19 and 5.8 ± 14.80 ETDRS letters, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote